DARZALEX® Mechanisms of Action


CD38 is expressed on hematopoietic cells, other cell types and tissues, and is overexpressed on multiple myeloma cells1,2

DARZALEX® inhibits tumor cell growth through immune-mediated, direct on-tumor, and immunoregulatory actions. DARZALEX® may also have an effect on normal cells1


DARZALEX® is the first CD38-targeted monoclonal antibody (mAb)1